Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients

M. Guazzi, G. Tumminello, G. Reina, M. Vicenzi, M. D. Guazzi

Research output: Contribution to journalArticle

Abstract

Background: Statins represent a modern mainstay of the drug treatment of coronary artery disease and acute coronary syndromes. Reduced aerobic work performance and slowed VO 2 kinetics are established features of the clinical picture of post-myocardial infarction (MI) patients. We tested the hypothesis that statin therapy improves VO 2 exercise performance in normocholesterolaemic post-MI patients. Materials and methods: According to a double-blinded, randomized, crossover and placebo-controlled study design, in 18 patients with uncomplicated recent (3 days) MI we investigated the effects of atorvastatin (20 mg day -1) on gas exchange kinetics by calculating VO 2 effective time constant (tau) during a 50-watt constant workload exercise, brachial artery flow-mediated dilatation (FMD) as an index of endothelial function, left ventricular function (echocardiography) and C-reactive protein (CRP, as an index of inflammation). Atorvastatin or placebo was given for 3 months each. Results: Atorvastatin therapy significantly improved exercise VO 2 tau and FMD, and reduced CRP levels. We did not observe changes in cardiac contractile function and relaxation properties during all study periods in either group. Conclusions: In post-MI patients exercise performance is a potential additional target of benefits related to statin therapy. Endothelial function improvement is very likely implicated in this newly described therapeutic property.

Original languageEnglish
Pages (from-to)454-462
Number of pages9
JournalEuropean Journal of Clinical Investigation
Volume37
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Exercise Therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Myocardial Infarction
Oxygen
Kinetics
Exercise
Dilatation
Drug therapy
Echocardiography
Placebos
Therapeutics
Brachial Artery
C-Reactive Protein
Acute Coronary Syndrome
Workload
Left Ventricular Function
Gases
Coronary Artery Disease
Atorvastatin Calcium
Inflammation

Keywords

  • Endothelium
  • Exercise
  • Oxygen kinetics
  • Statin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. / Guazzi, M.; Tumminello, G.; Reina, G.; Vicenzi, M.; Guazzi, M. D.

In: European Journal of Clinical Investigation, Vol. 37, No. 6, 06.2007, p. 454-462.

Research output: Contribution to journalArticle

Guazzi, M. ; Tumminello, G. ; Reina, G. ; Vicenzi, M. ; Guazzi, M. D. / Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients. In: European Journal of Clinical Investigation. 2007 ; Vol. 37, No. 6. pp. 454-462.
@article{36a20c7f38f342938fbbad770b62c01d,
title = "Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients",
abstract = "Background: Statins represent a modern mainstay of the drug treatment of coronary artery disease and acute coronary syndromes. Reduced aerobic work performance and slowed VO 2 kinetics are established features of the clinical picture of post-myocardial infarction (MI) patients. We tested the hypothesis that statin therapy improves VO 2 exercise performance in normocholesterolaemic post-MI patients. Materials and methods: According to a double-blinded, randomized, crossover and placebo-controlled study design, in 18 patients with uncomplicated recent (3 days) MI we investigated the effects of atorvastatin (20 mg day -1) on gas exchange kinetics by calculating VO 2 effective time constant (tau) during a 50-watt constant workload exercise, brachial artery flow-mediated dilatation (FMD) as an index of endothelial function, left ventricular function (echocardiography) and C-reactive protein (CRP, as an index of inflammation). Atorvastatin or placebo was given for 3 months each. Results: Atorvastatin therapy significantly improved exercise VO 2 tau and FMD, and reduced CRP levels. We did not observe changes in cardiac contractile function and relaxation properties during all study periods in either group. Conclusions: In post-MI patients exercise performance is a potential additional target of benefits related to statin therapy. Endothelial function improvement is very likely implicated in this newly described therapeutic property.",
keywords = "Endothelium, Exercise, Oxygen kinetics, Statin",
author = "M. Guazzi and G. Tumminello and G. Reina and M. Vicenzi and Guazzi, {M. D.}",
year = "2007",
month = "6",
doi = "10.1111/j.1365-2362.2007.01805.x",
language = "English",
volume = "37",
pages = "454--462",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Blackwell Publishing Ltd",
number = "6",

}

TY - JOUR

T1 - Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients

AU - Guazzi, M.

AU - Tumminello, G.

AU - Reina, G.

AU - Vicenzi, M.

AU - Guazzi, M. D.

PY - 2007/6

Y1 - 2007/6

N2 - Background: Statins represent a modern mainstay of the drug treatment of coronary artery disease and acute coronary syndromes. Reduced aerobic work performance and slowed VO 2 kinetics are established features of the clinical picture of post-myocardial infarction (MI) patients. We tested the hypothesis that statin therapy improves VO 2 exercise performance in normocholesterolaemic post-MI patients. Materials and methods: According to a double-blinded, randomized, crossover and placebo-controlled study design, in 18 patients with uncomplicated recent (3 days) MI we investigated the effects of atorvastatin (20 mg day -1) on gas exchange kinetics by calculating VO 2 effective time constant (tau) during a 50-watt constant workload exercise, brachial artery flow-mediated dilatation (FMD) as an index of endothelial function, left ventricular function (echocardiography) and C-reactive protein (CRP, as an index of inflammation). Atorvastatin or placebo was given for 3 months each. Results: Atorvastatin therapy significantly improved exercise VO 2 tau and FMD, and reduced CRP levels. We did not observe changes in cardiac contractile function and relaxation properties during all study periods in either group. Conclusions: In post-MI patients exercise performance is a potential additional target of benefits related to statin therapy. Endothelial function improvement is very likely implicated in this newly described therapeutic property.

AB - Background: Statins represent a modern mainstay of the drug treatment of coronary artery disease and acute coronary syndromes. Reduced aerobic work performance and slowed VO 2 kinetics are established features of the clinical picture of post-myocardial infarction (MI) patients. We tested the hypothesis that statin therapy improves VO 2 exercise performance in normocholesterolaemic post-MI patients. Materials and methods: According to a double-blinded, randomized, crossover and placebo-controlled study design, in 18 patients with uncomplicated recent (3 days) MI we investigated the effects of atorvastatin (20 mg day -1) on gas exchange kinetics by calculating VO 2 effective time constant (tau) during a 50-watt constant workload exercise, brachial artery flow-mediated dilatation (FMD) as an index of endothelial function, left ventricular function (echocardiography) and C-reactive protein (CRP, as an index of inflammation). Atorvastatin or placebo was given for 3 months each. Results: Atorvastatin therapy significantly improved exercise VO 2 tau and FMD, and reduced CRP levels. We did not observe changes in cardiac contractile function and relaxation properties during all study periods in either group. Conclusions: In post-MI patients exercise performance is a potential additional target of benefits related to statin therapy. Endothelial function improvement is very likely implicated in this newly described therapeutic property.

KW - Endothelium

KW - Exercise

KW - Oxygen kinetics

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=34249687024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249687024&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2362.2007.01805.x

DO - 10.1111/j.1365-2362.2007.01805.x

M3 - Article

C2 - 17537152

AN - SCOPUS:34249687024

VL - 37

SP - 454

EP - 462

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 6

ER -